A study analyzed data from 1,784 adult patients with moderate to severe plaque psoriasis to compare the effectiveness and safety of adalimumab monotherapy versus adalimumab with methotrexate. The findings revealed that there were no statistically significant differences in drug survival, treatment response, or serious adverse events between the two groups. Despite lower immunogenicity with methotrexate co-therapy, the addition of methotrexate did not improve effectiveness or safety, leading the investigators to conclude that methotrexate may not offer additional clinical benefit when used alongside adalimumab for plaque psoriasis. These results could inform treatment strategies and may prompt further research into alternative approaches.

Source: JAMA Dermatology